These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19189657)

  • 21. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
    Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
    Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
    Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
    Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression changes associated with erlotinib response in glioma cell lines.
    García-Claver A; Lorente M; Mur P; Campos-Martín Y; Mollejo M; Velasco G; Meléndez B
    Eur J Cancer; 2013 May; 49(7):1641-53. PubMed ID: 23374632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
    Carey KD; Garton AJ; Romero MS; Kahler J; Thomson S; Ross S; Park F; Haley JD; Gibson N; Sliwkowski MX
    Cancer Res; 2006 Aug; 66(16):8163-71. PubMed ID: 16912195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
    Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
    Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
    Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
    Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
    Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
    Yang JL; Qu XJ; Hayes VM; Brenner PC; Russell PJ; Goldstein D
    BJU Int; 2007 Jun; 99(6):1539-45. PubMed ID: 17346275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions.
    Kennedy CR; Tilkens SB; Guan H; Garner JA; Or PM; Chan AM
    Cancer Lett; 2013 Aug; 336(2):299-306. PubMed ID: 23523615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report.
    Zhou K; Yao H; Zhang X; Liu J; Qi Z; Xie X; Xu X; Zhou Y; Yu Z; Wang Z; Che Y; Huang Y
    Oncotarget; 2017 Jul; 8(30):50305-50313. PubMed ID: 28611289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma multiforme and the epidermal growth factor receptor.
    Friedman HS; Bigner DD
    N Engl J Med; 2005 Nov; 353(19):1997-9. PubMed ID: 16282174
    [No Abstract]   [Full Text] [Related]  

  • 37. Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B.
    Hamm R; Zeino M; Frewert S; Efferth T
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):78-86. PubMed ID: 25218289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting multiple kinases in glioblastoma multiforme.
    Sathornsumetee S; Reardon DA
    Expert Opin Investig Drugs; 2009 Mar; 18(3):277-92. PubMed ID: 19243279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines.
    Powe E; Parschauer D; Istifan J; Lin S; Duan H; Gryka R; Jean-Louis D; Tiwari AK; Amos S
    Front Pharmacol; 2022; 13():952169. PubMed ID: 36199696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid and convergent evolution in the glioblastoma multiforme genome.
    Shpak M; Goldberg MM; Cowperthwaite MC
    Genomics; 2015 Mar; 105(3):159-67. PubMed ID: 25576655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.